^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Mepact (mifamurtide)

    i
    Other names: CGP 19835, CGP 19835A, MLV 19835A, L-MTP-PE, liposomal MTP-PE, MTP-PE
    Company:
    Medison, Takeda
    Drug class:
    Macrophage stimulant, Monocyte stimulant
    Related drugs:
    9d
    SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, UNICANCER | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial primary completion date
    |
    doxorubicin hydrochloride • Mepact (mifamurtide)
    2ms
    Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
    P=N/A, N=80, Completed, Istituto Ortopedico Rizzoli | Trial completion date: Jun 2025 --> Oct 2024 | Trial primary completion date: Jun 2025 --> Oct 2024 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Mepact (mifamurtide)
    3ms
    The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide. (PubMed, Med Oncol)
    These results highlight the importance of TAMs in modulating treatment response. This study provides a preclinical proof of concept for the efficacy of combining mifamurtide with doxorubicin in managing chondrosarcoma, highlighting the potential of immunomodulator and chemotherapy co-treatment in improving treatment outcomes.
    Journal
    |
    TLR4 (Toll Like Receptor 4)
    |
    doxorubicin hydrochloride • Mepact (mifamurtide)
    4ms
    Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. (PubMed, J Clin Oncol)
    In this merged analysis with a risk-adapted strategy for nonmetastatic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well when mifamurtide, combined with HDIFO in case of poor response, was administered after surgery.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    cisplatin • doxorubicin hydrochloride • ifosfamide • methotrexate • Mepact (mifamurtide)
    4ms
    Tumor immune microenvironment-associated prognostic and mifamurtide-response gene signatures for localized osteosarcoma: a correlative study of the ISG/OS2 trial. (PubMed, Clin Cancer Res)
    A validated osteosarcoma TME prognostic gene signature has been identified, regardless of mifamurtide treatment. Importantly, a mifamurtide-related signature was also developed. Tumor-immune interactions possibly implicated in disease progression and treatment response were shown.
    Journal • Gene Signature
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Mepact (mifamurtide)
    6ms
    SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, UNICANCER | Trial primary completion date: Mar 2025 --> Sep 2025
    Trial primary completion date
    |
    doxorubicin hydrochloride • Mepact (mifamurtide)
    11ms
    Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatments. (PubMed, FASEB J)
    Incubating bone cores with mifamurtide induced a reduction of cellular markers and an increase in bone volume. This 3D bone core model has the potential to investigate osteosarcoma tumor microenvironment and provides a representative model for evaluation of novel therapies.
    Journal
    |
    CD68 (CD68 Molecule) • ENG (Endoglin)
    |
    Mepact (mifamurtide)
    1year
    Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells. (PubMed, AAPS PharmSciTech)
    The constructed long-circulating targeted liposomes co-loading DDP and mifamurtide significantly inhibited the cell viability, migration, invasion and cell apoptosis of MG-63 cells, improving the antitumor effect of DDP and mifamurtide in vitro. The constructed liposomal delivery system is suitable for co-loading DDP and mifamurtide to achieve active tumor targeting, supplying a new strategy for the treatment of OS.
    Journal
    |
    MMP14 (Matrix Metallopeptidase 14)
    |
    Mepact (mifamurtide)
    1year
    SARCOME13: Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, UNICANCER | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial primary completion date • Metastases
    |
    doxorubicin hydrochloride • Mepact (mifamurtide)
    over1year
    Chondrosarcoma Co-Culture 3D Model─An Insight to Evaluate Drugs Acting on TAMs. (PubMed, ACS Biomater Sci Eng)
    Finally, mifamurtide, an immunomodulator acting on TAMs, was evaluated on the most in vitro relevant model: 3D co-culture CH2879 model. Our results showed that it is now possible to develop 3D models that very accurately mimic what is found in vivo with the possibility of evaluating treatments specific to a tumor cell component.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    Mepact (mifamurtide)
    over1year
    Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
    |
    Mepact (mifamurtide)
    over1year
    Micros: Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Istituto Ortopedico Rizzoli | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
    |
    Mepact (mifamurtide)